AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04927013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outreach for Close Relatives
Description: The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
Study NCT05008328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy plus standard care during an SBT
Description: If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
Study NCT05008328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care during an SBT
Description: The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
Study NCT06118528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blur Obfuscation
Description: Blurring is applied to the RGB images.
Study NCT06118528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartoon Obfuscation
Description: Cartoonization is applied to the RGB images.
Study NCT06118528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edge Obfuscation
Description: A black background and simple outlines of objects/people are applied to the RGB images.
Study NCT06118528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Obfuscation (raw)
Description: No editing is performed on the RGB images.
Study NCT06642753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immediate implant with buccal plate augmentation using sticky bone
Description: * Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the pouch .
Study NCT06642753 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant with sticky bone as a filling material in the jumping gap
Description: Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the jumping gap.
Study NCT05548634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic
Study NCT05809687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DKP21102_C
Description: Placebo
Study NCT05809687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKP21102_B
Description: Treatment
Study NCT05809687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DKP21102_A
Description: Active Control
Study NCT05809687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKP21102_A
Description: Active Control
Study NCT06633224 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Specimen Collection
Description: Blood samples will be obtained throughout the course of the study
Study NCT06633224 — intervention group
Intervention type: OTHER
Intervention: Stool Specimen Collection
Description: Stool samples will be obtained throughout the course of the study
Study NCT06633224 — intervention group
Intervention type: OTHER
Intervention: Quality of Life (QOL) Questionnaires
Description: Surveys will be given throughout the course of the study.
Study NCT04924322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
Study NCT06166277 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation procedure
Description: Cardioneuroablation procedure or permanent pacemaker placement
Study NCT05502250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, cisplatin and tislelizumab
Description: All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line.
Study NCT06453616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hello bundle
Description: Hello Bundle comprises : posters, email reminders, morning huddles, hello jar, hello board and a led example.~Participants will have to fill out a questionnaire before and after the intervention.~The main components of the questionnaire include respondent's characteristics, visitation policies, team-family interactions, family-centeredness (VAS), and practices at the end of life. ICU-conflicts (VAS), symptoms of burnout, and a VAS to rank the ethical climate, satisfaction with work, and intent to leave the job. Symptoms of burnout will be measured using the validated version of the 22-item Maslach Burnout Inventory (MBI, Human Services version)
Study NCT06242028 — intervention group
Intervention type: DRUG
Intervention: Group P
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
Study NCT06242028 — intervention group
Intervention type: DRUG
Intervention: Group S
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
Study NCT04754087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vivacit-E and Longevity (HXLPE) Liners
Description: This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
Study NCT05268380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19, TB and HIV diagnosis
Description: GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
Study NCT04939155 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 mRNA vaccine
Description: mRNA vaccine for COVID
Study NCT05412433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Level
Description: Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations
Study NCT05412433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel
Description: Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts
Study NCT05412433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care
Study NCT04912167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
Study NCT04912167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
Study NCT04912167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
Study NCT06334679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Gel Packet Application
Description: Cold gel packs will be placed on the burn areas of the patients in the maturation phase and applied for 20 minutes.
Study NCT05058391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elaprase
Description: Elaprase IV infusion.
Study NCT04626713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-Computer Interface
Description: Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
Study NCT04982133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment
Description: At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk.
Study NCT04982133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment
Description: At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk.
Study NCT05779163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-033 for Injection
Description: Initial dose - MTD; Q2W; intravenous infusion
Study NCT01543750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminopyridine
Study NCT01543750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05381220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: Patients will receive early mobilization measures within 24 to 48 hours after the onset of stroke.
Study NCT05338047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
Study NCT05338047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegfilgrastim
Description: Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
Study NCT06197009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SCT650C
Description: Administered SC
Study NCT06197009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCT650C
Description: Administered SC
Study NCT05176600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and bimanual serious games
Description: Patients will undergo a bimanual 30-session robotic rehabilitation, using the robot ALEx RS with the bimanual configuration and the related serious games. Each session will last 45 minute. Daily sessions will be provided, five days a week.
Study NCT05176600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and unimanual serious games
Description: Patients will undergo a unimanual 30-session robotic rehabilitation, using the robot ALEx RS with the unimanual configuration and the related serious games.Daily sessions will be provided, five days a week.
Study NCT05660655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG Oral Tablet
Description: baricitinib 4 mg once daily
Study NCT05660655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib 2 MG
Description: baricitinib 4mg once daily in group A
Study NCT05108779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF32004
Description: In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
Study NCT04724187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: it is prostaglandin E1 .
Study NCT04724187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: it stimulates uterine contractions
Study NCT04724187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: it stimulates uterine contractions
Study NCT05662826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-based Social Physical Activity
Description: Exercise, group discussions, role-playing skits, and group painting done in a virtual setting.
Study NCT06563011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Counselling
Description: Tailored Dietary Counselling
Study NCT05698186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thero2-01S22
Description: Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Study NCT05698186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Study NCT05698186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thero2-01S22
Description: Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Study NCT05459597 — intervention group
Intervention type: DRUG
Intervention: antiepileptic drugs
Description: phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
Study NCT06559670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: - Collection and analysis of blood samples
Study NCT04820920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP
Description: LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postnatal mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
Study NCT04820920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaCBT
Description: CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
Study NCT04820920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions.
Study NCT04819594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elequil aromatabs ®
Description: 100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
Study NCT05422391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 3 day caloric restriction/metabolic reset
Description: Participants will consume \~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
Study NCT06561009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-BAFFR CART
Description: Anti-BAFFR CART
Study NCT06559566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG
Description: The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
Study NCT05009992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Given orally (PO)
Study NCT06559566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BCT
Description: The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
Study NCT05760144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
Study NCT05760144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel implant
Description: The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
Study NCT06553664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treat with Vibrabot capsules for at least 7 weeks
Description: Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
Study NCT05622799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Medicine Training Program
Description: A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
Study NCT06017102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wired magnetic assisted capsule endoscopy
Description: once
Study NCT06257212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccine (Danish strain 1331)
Description: Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
Study NCT06257212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMR Vaccine
Description: Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
Study NCT06257212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous saline + intradermal saline at inclusion and after 3 months.
Study NCT05009992 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT06323408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue, blood, cerebrospinal-spinal fluid
Description: Processing, analysis